Navigation Links
JAZZ PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2013 FINANCIAL RESULTS
Date:8/6/2013

d to pro forma net sales of $12.4 million in the same period of 2012.  "Other" includes products acquired in the EUSA Pharma and Azur Pharma transactions that are not mentioned above. 

Operating Expenses and Other Operating expenses for the second quarter of 2013 increased to $131.2 million compared to $84.8 million for the second quarter of 2012.  Operating expenses increased over the prior year period for the following reasons:

  • Cost of product sales for the second quarter of 2013 was $25.0 million compared to $12.3 million for the same period in 2012.  The increase in the 2013 period was primarily due to higher net sales and a change in product mix. Gross margin for the second quarter of 2013, as a percentage of product sales, was 87.9% compared to 90.0% for the same period in 2012.  Our gross margin percentage in the second quarter of 2013 as compared to the same period in 2012 was lower primarily due to lower gross margins on products acquired as part of the EUSA Pharma acquisition.
  • Selling, general and administrative ("SG&A") and research and development ("R&D") expenses for the second quarter of 2013 totaled $86.8 million on a GAAP basis compared to $59.5 million for the same period of 2012.  The increase reflected higher headcount and related expenses due primarily to the expansion of our business and an increase in the fair value of contingent consideration related to the EUSA Pharma acquisition, partially offset by lower transaction and integration costs.  Adjusted SG&A and R&D expenses for the second quarter of 2013 totaled $70.6 million compared to $44.0 million for the same period in 2012.
  • Intangible asset amortization for the second quarter of 2013 was $19.4 million compared to $13.0 million for the same period in 2012.  The increase was primarily related to amortization of intangible assets acquired as part of the EUSA Pharma acquisition.
  • Second quart
    '/>"/>

    SOURCE Jazz Pharmaceuticals plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Cumberland Pharmaceuticals Reports Second Quarter Financial Results
    2. Inovio Pharmaceuticals Responds to Market Activity
    3. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
    4. Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb
    5. Avanir Pharmaceuticals to Participate in Two Conferences in August
    6. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
    7. AcelRx Pharmaceuticals to Present at Canaccord Genuity 33rd Annual Growth Conference
    8. Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients with Rheumatoid Arthritis
    9. Intercept Pharmaceuticals to Present at the Wedbush Securities Life Sciences Management Access Conference
    10. GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition
    11. GW Pharmaceuticals plc Reports 2013 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
    (Date:12/17/2014)... STUTTGART , Alemania, December 17, 2014 ... del año anterior, con un alto nivel de gasto ... pasado año fiscal 2013/14 (finalizado el 30 de septiembre ... por ciento a 4.287 millones de euros (año anterior: ... de la moneda desfavorables. Las ganancias (EBIT) crecieron un ...
    (Date:12/17/2014)... , Dec. 17, 2014  Northstar Global ... Depository Trust Company (DTC) has made their final ... Chill on the Company,s stock effective December 15, ... common stock for depository and book entry transfer ... Company is now once again fully "DTC Eligible", ...
    Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS confirma su posición en un entorno difícil 2Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3
    ... 8, 2011 INNOPHARMA LLC announced ... for levetiracetam injection (the generic equivalent of Keppra® injection from ... injectable drug, INNOPHARMA entered into a license agreement with X-GEN ... About INNOPHARMA: INNOPHARMA ...
    ... 8, 2011 Echo Therapeutics, Inc. (Nasdaq: ... as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) ... delivery, today announced the receipt of notices of issuance ... notices of registration for the trademarks PRELUDE and SYMPHONY. ...
    Cached Medicine Technology:Echo Therapeutics Announces Multiple Patents and Trademark Grants 2Echo Therapeutics Announces Multiple Patents and Trademark Grants 3
    (Date:12/19/2014)... December 20, 2014 It’s very easy to ... something that is put to the wayside until Christmas and ... have that travel “itch” and that burning desire to just ... families on their journey to Telluride with a no-fuss, affordable ... to and from the resort, and ensure that all accommodations ...
    (Date:12/19/2014)... Silver Dollar City is picking up ... the first time ever, Silver Dollar City has a title ... 2015, listing the park’s wood coaster Outlaw Run as the ... announced this week, Silver Dollar City is named in CNN ... USA Today’s 10Best awards for “Best Public Lights Display,” and ...
    (Date:12/19/2014)... 2014 The Medspa at Hendrick in ... from respected cosmetic brand Juvéderm. Voluma XC treats volume ... The Medspa at Hendrick is pleased to be able ... technology to its clients. , Voluma is the first ... to treat the mid-face and cheek area. This non-invasive ...
    (Date:12/19/2014)... -- Potentially illness-causing E. coli bacteria were found on ... to a new study. Researchers checked cilantro, basil ... markets in Los Angeles and Orange counties in California, ... samples tested, 24 percent were positive for E. coli. ... researchers. Both types of bacteria can cause sometimes ...
    (Date:12/19/2014)... December 19, 2014 Surviving Mesothelioma says thousands ... information indicates that these pipes can leach asbestos into drinking ... the full story on the Surviving Mesothelioma website. ... of natural asbestos deposits, decaying water mains made of asbestos ... , To protect consumers from mesothelioma , water ...
    Breaking Medicine News(10 mins):Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Silver Dollar City Nets New Titles: Guinness Book of World Records, Plus CNN Travel, USA Today & Fodor’s Top Places for Christmas Lights 2Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:E. Coli Germs Found on Farmers Market Herbs 2Health News:Surviving Mesothelioma Warns of Potential Mesothelioma Risk from Cement Water Pipes 2
    ... The leading medical ... shorter working hours for junior doctors. , ... London (PRWeb UK) April 23, 2010 -- HCL Thames Medics , the ... said today that greater use of flexible and locum doctors is vital for ...
    ... ... Team Up Once Again For Annual Charity Race Across The Golden Gate Bridge, , ... (PRWEB) April 22, 2010 -- Over ... race,s reputation as one of San Francisco,s most unique community-oriented and volunteer organized races. ...
    ... investigate whether there is a link between the use of ... The cohort study on mobile communications (COSMOS) forms part of ... study will run for 20-30 years and will follow the ... European countries. The UK arm of COSMOS is being led ...
    ... cancer and other diseases, precise analysis of specific proteins ... theTechnische Universitaet Muenchen (TUM), together with Fujitsu Laboratories of ... only recognizes proteins that are characteristic for specific diseases, ... through the influence of disease or drugs. ...
    ... April 21, 2010 Although genetics is the ... genes affect intelligence remains largely unknown. A multi-institution team ... USTAR researcher has found that the brain gene STX1A ... displayed by patients with Williams Syndrome (WS). The study ...
    ... for a long time that children with Down syndrome tend ... other children. But pediatricians needing to record growth milestones at ... based on data collected more than 25 years ago. Since ... care of children with Down syndrome. In addition, the demographics ...
    Cached Medicine News:Health News:HCL Thames Medics says more locum doctors could help address European Working Time Directive shortage 2Health News:The 26th Running of San Francisco's Presidio 10 Race Was a Win For Local Charities, the Community and the Environment 2Health News:The 26th Running of San Francisco's Presidio 10 Race Was a Win For Local Charities, the Community and the Environment 3Health News:Health impacts of mobile phone use to be explored in huge new study 2Health News:Health impacts of mobile phone use to be explored in huge new study 3Health News:Biosensor chip enables high-sensitivity protein analysis for disease diagnosis 2Health News:Study of Williams syndrome patients reveals specific gene's role in intelligence 2Health News:Study of Williams syndrome patients reveals specific gene's role in intelligence 3Health News:Nutrition researchers to develop new growth charts for children with Down syndrome 2
    PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
    ... KWIK-QC Slides have a positive and ... sample inoculation. With these slides, perform QC ... ,Laboratories enhance their education and training programs ... and interpretation, all on one slide! KWIK-QC ...
    Each slide contains Giardia lamblia trophozoites applied as a mono-layer to the side....
    Each slide contains a high yield of concentrated C. parvum oocysts within the positive control well. A negative control well is also included....
    Medicine Products: